Related Experiment Video
Updated: Oct 16, 2026
Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
Published on: April 14, 2016
High Burden and Phenotype-Specific Variability of Pain Polypharmacy in Early Autoimmune Rheumatic Diseases: A 14-Year
Di Lu1, Md Belal Hossain2, Kristen Cunanan1
1Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Background:
Pain drives disability and medication use in autoimmune rheumatic diseases (ARDs), even when inflammation is controlled. The extent of pain-related polypharmacy across ARDs and chronic overlapping pain conditions (COPCs) remains poorly characterized. We aimed to quantify first-year pain medication burden following ARD diagnosis and examine variations by disease, COPC status, and time.
Methods:
Using the Merative MarketScan Commercial Claims database, we identified adults newly diagnosed with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, Sjögren's disease, or systemic sclerosis (2008-2021). We analyzed pain-related medications across 10 pharmacologic categories during the first year postdiagnosis. Polypharmacy measures included counts of distinct pain medications, medication categories, ≥ 5 and ≥ 10 medication thresholds, and the Medication Quantification Scale.
Findings:
Among 149 742 adults with newly diagnosed ARDs, 57.6% had at least one COPC. During the first year after diagnosis, patients filled a mean of 9.0 distinct pain medications and 47.9% met criteria for ≥ 5 medications; 30.5% met criteria for ≥ 10 medications. Ankylosing spondylitis demonstrated the highest medication burden (mean 11.6 medications; 57.5% with ≥ 5 medications; 37.9% with ≥ 10 medications). Patients with fibromyalgia had consistently higher medication burden across ARDs and were the only COPC group in whom prescribing increased from 2015 onward. Overall medication burden rose from 2008 to 2014-2015 and declined thereafter; however, absolute levels remained high.
Interpretation:
Pain-related polypharmacy is common early after ARD diagnosis and varies substantially by disease and pain phenotype. Despite modest declines from 2015 onward, medication burden remains high, underscoring the need for phenotype-informed, nonpharmacologic, and deprescribing strategies in rheumatology.
